INS and metastatic neoplasm: Various insulin-lowering dietary strategies have been tested preclinically and clinically, showing improvements in metabolic factors that are associated with cancer mortality; however, improvement in cancer-specific endpoints have not been demonstrated and thus these strategies cannot yet be recommended as part of routine cancer care in patients with metastatic disease.